Jessica Allegretti

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada adn her IBD training at Cedars-SInai Medical Center, Los Angeles, CA. Dr. Dubinsky is a proud recipient of the 2022 Sherman Prize for Excellence in Crohn’s and Colitis and a 2024 Jacobi Medallion winner for her contibutions to Mount Sinai. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology and Nutrition, as well as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and Co-director of the Marie and Barry Lipman Preconception and Pregnancy Planning Clinic at Mount Sinai Hospital, New York, She is a Professor of both Pediatrics and Medicine at the Icahn School of Medicine, Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 400 peer reviewed journals including New England Journal of Medicine, Lancet, Gastroenterology, The American Journal of Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and of Crohn's and Colitis .

Professor Remo Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Canada. He serves as the Dean of MD Admissions and Director of the IBD Fellowship Program. He also holds the Crohn’s Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease.

He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and received the 2024 Crohn’s Colitis Canada Research Leadership Award for his contributions to the field. Since 2020 he has been a Clarivate Research Scholar for being cited in the top one percent of researchers in the world. He has co-authored over 500 manuscripts, 20 book chapters and 825 abstracts, including publications in journals such as the New England Journal of Medicine, The Lancet, JAMA, Nature, and Annals of Internal Medicine.

Prof. Panaccione’s main research interest is the design and implementation of clinical trials. He has been the principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in subjects with IBD.

Dr. Rieder is Vice Chair and Co-Director of the IBD section at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction and therapy of intestinal fibrosis. Dr. Rieder has published more than 200 articles and book chapters and has been recognized for his expertise as indicated through invitations to clinical guideline steering committees of the European Crohn’s and Colitis Organization (ECCO). He is lead author of the ECCO guidelines on Ulcerative colitis and lead author of the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He received multiple international invitations as a speaker, session chair or conference faculty. Dr. Rieder serves as an abstract reviewer for all major GI conferences, he is past associate editor (Clinical and Translational Gastroenterology) and on several editorial boards of medical journals. He is proud of his significant ties to the ECCO, which he served as the chair of Y-ECCO, member of the ECCO operational board, prior Y-ECCO committee member and member of the scientific committee. He is past chair of REACH-IBD and Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation. Dr. Rieder is the leading PI on the international Stenosis Therapy and Research (STAR) Consortium with the goal to build a pathway to test anti-fibrotic medications in stricturing Crohn’s disease. He received the Sherman Emerging Leader Prize in 2019.

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and Deputy Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. Dr. Rubin is currently a senior editor of the 12 edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Guidelines for ulcerative colitis.

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Hans Herfarth is Director of the Multidisciplinary IBD Center at the University of North Carolina. His primary research interests focus on the development and evaluation of novel diagnostic and therapeutic approaches for patients with inflammatory bowel diseases (IBD). His work is particularly centered on the conceptualization and conduct of investigator-initiated clinical studies in IBD, supported by funding from the NIH, the Crohn’s & Colitis Foundation, and private and industry-associated foundations. Dr. Herfarth has authored more than 350 journal articles, book chapters, and review articles related to IBD.

Maria T. Abreu, MD, is a physician-scientist and gastroenterologist who specializes in inflammatory bowel diseases (IBD). She received her medical degree from the University of Miami School of Medicine and completed a residency in medicine at the Brigham and Women’s Hospital. She served as an Associate Professor of Medicine at Mount Sinai School of Medicine (and head of their IBD Center), a Professor of Medicine and Microbiology & Immunology at the University of Miami School of Medicine (and Director of the Crohn’s and Colitis Center), and currently is the Executive Director of the F. Widjaja IBD Institute at Cedars-Sinai Medical Center; in past years, she has served as the President of the American Gastroenterological Association (AGA) and the Chair of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Dr. Abreu has 30 years of leadership experience in basic, translational, and clinical research, and has authored almost 300 peer-reviewed articles, book chapters, and reviews. Her work has received multiple awards, including the 2019 Sherman Prize from the Bruce and Cynthia Sherman Charitable Foundation for outstanding achievements in IBD and Healio’s Lifetime Disruptor Award for addressing critical unmet needs in IBD. Her research focuses on interactions between the gut microbiome and the innate immune system in the development of IBD and IBD-associated colon cancer. Currently, Dr. Abreu’s team is investigating how diet may shape the gut microbiome and alleviate IBD symptoms. Understand the underlying mechanisms can help us develop targeted treatment strategies to help patients live their best lives.

Gastroenterologist with an interest in inflammatory bowel diseases.

Dr. Hudesman is Director of the Inflammatory Bowel Disease Center at NYU Langone Health. He is Professor of Medicine at the NYU School of Medicine.

Dr. Hudesman specializes in the diagnosis and treatment of inflammatory bowel disease (IBD) and in the provision of integrated, seamless, patient-centered care. His research is focused on the development of biomarkers and evaluation and optimization of new medical therapies for the treatment of both Crohn’s disease and ulcerative colitis.

Dr. Hudesman served on the Educational Affairs Committee of the American College of Gastroenterology, and the Professional Membership Committee of the Crohn’s Colitis Foundation, and is currently on the Quality Committee of the American Gastroenterological Association.

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Hans Herfarth is Director of the Multidisciplinary IBD Center at the University of North Carolina. His primary research interests focus on the development and evaluation of novel diagnostic and therapeutic approaches for patients with inflammatory bowel diseases (IBD). His work is particularly centered on the conceptualization and conduct of investigator-initiated clinical studies in IBD, supported by funding from the NIH, the Crohn’s & Colitis Foundation, and private and industry-associated foundations. Dr. Herfarth has authored more than 350 journal articles, book chapters, and review articles related to IBD.

Maria T. Abreu, MD, is a physician-scientist and gastroenterologist who specializes in inflammatory bowel diseases (IBD). She received her medical degree from the University of Miami School of Medicine and completed a residency in medicine at the Brigham and Women’s Hospital. She served as an Associate Professor of Medicine at Mount Sinai School of Medicine (and head of their IBD Center), a Professor of Medicine and Microbiology & Immunology at the University of Miami School of Medicine (and Director of the Crohn’s and Colitis Center), and currently is the Executive Director of the F. Widjaja IBD Institute at Cedars-Sinai Medical Center; in past years, she has served as the President of the American Gastroenterological Association (AGA) and the Chair of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Dr. Abreu has 30 years of leadership experience in basic, translational, and clinical research, and has authored almost 300 peer-reviewed articles, book chapters, and reviews. Her work has received multiple awards, including the 2019 Sherman Prize from the Bruce and Cynthia Sherman Charitable Foundation for outstanding achievements in IBD and Healio’s Lifetime Disruptor Award for addressing critical unmet needs in IBD. Her research focuses on interactions between the gut microbiome and the innate immune system in the development of IBD and IBD-associated colon cancer. Currently, Dr. Abreu’s team is investigating how diet may shape the gut microbiome and alleviate IBD symptoms. Understand the underlying mechanisms can help us develop targeted treatment strategies to help patients live their best lives.

Gastroenterologist with an interest in inflammatory bowel diseases.

Dr. Hudesman is Director of the Inflammatory Bowel Disease Center at NYU Langone Health. He is Professor of Medicine at the NYU School of Medicine.

Dr. Hudesman specializes in the diagnosis and treatment of inflammatory bowel disease (IBD) and in the provision of integrated, seamless, patient-centered care. His research is focused on the development of biomarkers and evaluation and optimization of new medical therapies for the treatment of both Crohn’s disease and ulcerative colitis.

Dr. Hudesman served on the Educational Affairs Committee of the American College of Gastroenterology, and the Professional Membership Committee of the Crohn’s Colitis Foundation, and is currently on the Quality Committee of the American Gastroenterological Association.